PARP1/NAMPT-IN-1

PARP1/NAMPT-IN-1 是一种强效的双重 PARP1 和 NAMPT 抑制剂(IC50 值分别为 1.2 nM 和 6.7 nM),可通过破坏同源重组修复 (HRR) 通路导致 DNA 双链断裂 (DSB) 积累,诱导细胞周期阻滞和凋亡 (apoptosis) 并具有抗迁移作用,在乳腺癌异种移植模型中表现出优异的抗肿瘤效果,可用于三阴性乳腺癌 (TNBC) 的研究。
产品编号: MS-J48229 CAS No.: 3084810-86-3 分子式: C35H31FN6O3 分子量: 602.66
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PARP1/NAMPT-IN-1 是一种强效的双重 PARP1 和 NAMPT 抑制剂(IC50 值分别为 1.2 nM 和 6.7 nM),可通过破坏同源重组修复 (HRR) 通路导致 DNA 双链断裂 (DSB) 积累,诱导细胞周期阻滞和凋亡 (apoptosis) 并具有抗迁移作用,在乳腺癌异种移植模型中表现出优异的抗肿瘤效果,可用于三阴性乳腺癌 (TNBC) 的研究。

生物实验数据

生物活性 PARP1/NAMPT-IN-1 is a potent dual PARP1 and NAMPT inhibitor (IC50 = 1.2 nM and 6.7 nM, respectively) that disrupts the homologous recombination repair (HRR) pathway, leading to the accumulation of DNA double-strand breaks (DSBs), induces cell cycle arrest and apoptosis, exhibits anti-migration activity, demonstrates excellent antitumor efficacy in breast cancer xenograft models, and can be used for the study of triple-negative breast cancer (TNBC).
IC50 & Target

PARP1

1.2 nM (IC50)

NAMPT

6.7 nM (IC50)

体外研究
(In Vitro)

PARP1/NAMPT-IN-1 (compound 10 n) (24 小时至 7 天) 对 MDA-MB-231 细胞 (IC50 = 1.28 nM) 和 MDA-MB-468 细胞 (IC50 = 0.46 nM) 显示出选择性抗增殖活性。PARP1/NAMPT-IN-1 对 MCF-10A 细胞的细胞毒性作用可忽略不计 (IC50 > 20 μM)。
PARP1/NAMPT-IN-1 (0.3-1 μM;48 小时) 可诱导 MDA-MB-231 细胞发生细胞周期阻滞和凋亡。
PARP1/NAMPT-IN-1 (0.3-1 μM;48 小时) 可破坏 HRR 通路,诱导 MDA-MB-231 细胞发生合成致死并引发 DSB。
PARP1/NAMPT-IN-1 (0.3-1 μM;48 小时) 对 MDA-MB-231 细胞具有显著的抗迁移作用。
PARP1/NAMPT-IN-1 (0.3-1 μM; 48 h) 可显著提高体外培养的 4T1 细胞中 cGAS 的表达水平以及 STING、TBK1 和 IRF3 的磷酸化水平,提示其可激活肿瘤内 STING 信号通路。
PARP1/NAMPT-IN-1 (0.3-1 μM; 48 h) 可增强 MDA-MB-231 细胞中 TBK1 和 IRF3 的磷酸化水平。

Cell Cycle Analysis

Cell Line: MDA-MB-231 cells
Concentration: 0.3 μM, 1 μM
Incubation Time: 48 h
Result: Dose-dependently arrested MDA-MB-231 cells at G2/M phase with a low concentration (0.3 μM).

Apoptosis Analysis

Cell Line: MDA-MB-231 cells
Concentration: 0.3 μM, 1 μM
Incubation Time: 48 h
Result: Induced a dose-dependent increase in apoptosis.
Upregulated pro-apoptotic Bax and cleaved PARP while downregulating antiapoptotic Bcl-2.

Immunofluorescence

Cell Line: MDA-MB-231 cells
Concentration: 0.3 μM, 1 μM
Incubation Time: 48 h
Result: Induced significantly higher nuclear γH2AX levels.

Western Blot Analysis

Cell Line: MDA-MB-231 cells
Concentration: 0.3 μM, 1 μM
Incubation Time: 48 h
Result: Significantly suppressed expression of all tested HRR components (BRCA1, CtIP, Mre11, RAD51, p-RPA32).

Cell Migration Assay

Cell Line: MDA-MB-231 cells
Concentration: 0.3 μM, 1 μM
Incubation Time: 48 h
Result: Inhibited MDA-MB-231 cell migration.
Potently downregulated the promigratory markers MMP2 and N-cadherin (typically elevated in epithelial-mesenchymal transition (EMT)) while upregulating E-cadherin (an epithelial marker associated with reduced motility that is frequently lost in EMT).

Western Blot Analysis

Cell Line: 4T1 cells and MDA-MB-231 cells
Concentration: 0.3 μM, 1 μM
Incubation Time: 48 h
Result: Significantly increased cGAS level and phosphorylation of STING, TBK1, and IRF3 in 4T1 cells.
Enhanced TBK1 and IRF3 phosphorylation in MDA-MB-231 cells.
体内研究
(In Vivo)

PARP1/NAMPT-IN-1 (compound 10 n) (5-10 mg/kg;腹腔注射;每日一次;连续 14 天) 在 MDA-MB-231 异种移植模型中具有良好的抗肿瘤效果和安全性。
PARP1/NAMPT-IN-1 (5 mg/kg;腹腔注射;每日一次;连续 5 天) 可有效抑制 4T1 小鼠异种移植模型中的肿瘤生长。
PARP1/NAMPT-IN-1 (5 mg/kg;腹腔注射;每天一次;持续 14 天) 在 4T1 鼠 BRCA 野生型 TNBC 模型中激活 STING 通路以驱动抗肿瘤免疫。

Animal Model: Female BALB/c nude mice (6-8 weeks old), received subcutaneous injections of MDA-MB-231 cells (5 × 106 cells per mouse in 0.1 mL PBS) in the right flank.
Dosage: 5 mg/kg, or 10 mg/kg
Administration: Intraperitoneal (IP) injection; once daily; for 14 days
Result: At 5 mg/kg achieved a notable tumor growth inhibition (TGI = 59.98%).
No significant weight loss or mortality at 5 mg/kg.
At 10 mg/kg, significantly enhanced TGI to 83.37%, while maintaining a favorable safety profile, as evidenced by no mortality and significant weight loss.
Animal Model: Female immunocompetent BALB/c mice (6-8 weeks old) were intravenously injected with 4T1 cells (5 × 105 cells per mouse in 0.1 mL PBS).
Dosage: 5 mg/kg
Administration: Intraperitoneal (IP) injection; once daily; for 5 days
Result: Markedly reduced the formation of lung metastatic nodules compared to the control group.
H&E staining revealing significantly fewer metastatic lesions in lung tissues.
Animal Model: Female immunocompetent BALB/c mice (6-8 weeks old) were intravenously injected with 4T1 cells (5 × 105 cells per mouse in 0.1 mL PBS).
Dosage: 5 mg/kg
Administration: Intraperitoneal (IP) injection; once daily; for 14 days
Result: Demonstrated excellent antitumor efficacy (TGI = 70.18%) without significant weight loss or mortality.
Significantly reduced proliferation (Ki67 IHC) and caused extensive tissue destruction (H&E).
Markedly increased tumor-infiltrating CD3+ and CD8+ T cells.
Suppressed the recruitment of MDSCs, evidenced by reduced coexpression of CD11b and Ly6G in multiplex immunofluorescence staining.
Significantly elevated cGAS levels and phosphorylation of STING, TBK1, and IRF3.

化学信息

分子量 602.66
分子式 C35H31FN6O3
CAS No. 3084810-86-3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础